G1 Therapeutics, Inc. (NASDAQ:GTHX) Shares Sold by Raymond James & Associates

Raymond James & Associates cut its stake in shares of G1 Therapeutics, Inc. (NASDAQ:GTHX) by 38.9% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 565,555 shares of the company’s stock after selling 360,221 shares during the period. Raymond James & Associates owned approximately 1.09% of G1 Therapeutics worth $1,725,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. JPMorgan Chase & Co. lifted its position in G1 Therapeutics by 5.6% during the 1st quarter. JPMorgan Chase & Co. now owns 2,149,526 shares of the company’s stock worth $5,761,000 after acquiring an additional 113,904 shares in the last quarter. Vanguard Group Inc. raised its position in shares of G1 Therapeutics by 4.1% in the 3rd quarter. Vanguard Group Inc. now owns 1,686,453 shares of the company’s stock valued at $21,063,000 after purchasing an additional 65,952 shares in the last quarter. Millennium Management LLC raised its position in shares of G1 Therapeutics by 42.6% in the 4th quarter. Millennium Management LLC now owns 1,671,859 shares of the company’s stock valued at $9,078,000 after purchasing an additional 499,363 shares in the last quarter. State Street Corp raised its position in shares of G1 Therapeutics by 1,038.1% in the 3rd quarter. State Street Corp now owns 1,618,381 shares of the company’s stock valued at $20,214,000 after purchasing an additional 1,476,175 shares in the last quarter. Finally, BlackRock Inc. raised its position in shares of G1 Therapeutics by 11.0% in the 3rd quarter. BlackRock Inc. now owns 1,519,657 shares of the company’s stock valued at $18,980,000 after purchasing an additional 150,376 shares in the last quarter. 24.21% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts have issued reports on GTHX shares. Wedbush reaffirmed an “outperform” rating and issued a $5.00 target price (up from $4.00) on shares of G1 Therapeutics in a research report on Wednesday, February 28th. Needham & Company LLC reaffirmed a “buy” rating and issued a $12.00 target price on shares of G1 Therapeutics in a research report on Friday, April 12th.

G1 Therapeutics Price Performance

Shares of NASDAQ GTHX opened at $4.28 on Thursday. G1 Therapeutics, Inc. has a twelve month low of $1.08 and a twelve month high of $5.00. The company has a current ratio of 3.87, a quick ratio of 3.45 and a debt-to-equity ratio of 1.46. The company has a market capitalization of $223.54 million, a price-to-earnings ratio of -4.51 and a beta of 1.73. The business has a 50 day simple moving average of $3.64 and a 200-day simple moving average of $2.85.

G1 Therapeutics (NASDAQ:GTHX) last issued its quarterly earnings results on Wednesday, February 28th. The company reported ($0.21) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.06. G1 Therapeutics had a negative return on equity of 106.04% and a negative net margin of 58.13%. The business had revenue of $14.87 million during the quarter, compared to the consensus estimate of $12.83 million. During the same period in the previous year, the business earned ($0.73) EPS. As a group, equities research analysts expect that G1 Therapeutics, Inc. will post -0.64 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Rajesh Malik sold 28,600 shares of the company’s stock in a transaction on Monday, February 12th. The stock was sold at an average price of $4.62, for a total transaction of $132,132.00. Following the completion of the transaction, the insider now directly owns 169,938 shares in the company, valued at approximately $785,113.56. The sale was disclosed in a document filed with the SEC, which is available through this link. 8.23% of the stock is owned by company insiders.

G1 Therapeutics Profile

G1 Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer.